1Goldhirsch A, Glick J H, Gelber R D, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer[J]. J natl Cancer Inst 90, 1998, 19 (18): 3817.
2Goldhirsch A, Gliek J H, Gelber R D, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer[J]. J Clin Oncol, 2001, 19(18): 3817.
3National Institutes of Health Consensus Development Conference[J]. J Natl Cancer Inst Monogr, 2001, 30: 1.
4Carlson R W, Edge S B, Theriault R L. NCCN: Breast cancer[J]. Cancer Control, 2001, 8(6 Suppl 2) : 54.
5Galea M H, Blamey R W, Elston C E, et al. The Nottingham prognostic index in primary breast cancer[J]. Breast Cancer Res Treat, 1992, 22: 207.
6Nabholtz J M, Pienkowski T, Maekey J, et al. Phase Ⅲ trial comparing TAC with FAC in the adjuvant treatment of node positive breast cancer patients: interim analysis[J].ASCO, 2002.
7Fisher B, Anderson S, Wolmark N, et al. Cheznotherapy with or without tamoxifen for patients with ER-negative breast cancer and negative nodes: Result from NSABP B-23[J]. J Clin Oneol, 2001, 19: 931.
8Hutchins L, Green S, Ravdin P, et al. CMF versus CAF with and without tamoxlfen in high-risk node negative breast cancer patients and a natural history follow-up study in lowrisk node negative patients: First results of Intergroup trial INT 0102[J]. Proc Am Soc Clin Oncol, 1998, 17: la.
9Levine M, Bramwell V, Pritchard K, et al. Randomized trial of intensive cyelophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluomuraeil in premenopansal women with nodepositive breast cancer[J]. National Cancer Institute of Canada Clinical Trials Group, J Clin Oneol, 1998, 16: 2651.
10Fisher B, Gunduz N, Coyle J, et al. Presence of a growthstimulating factor in serum following primary tumor removal in mice[J]. Cancer Res, 1989, 49(8): 1996.
10Lo SS, Wang HC, Shyr YM. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy [ J ] ? J Surg oncol, 1994,57(2) :94-96.
